NO ADDITIONAL TIME WITHOUT COMPROMISE

System Configuration

DIQ 5R

Acquisition

203MBq /5.5mCi 18F- FDG
66 minute uptake
15 minute acquisition

Patient BMI

26.2

Takeaway

MotionFree and Q.Clear provides motion corrected images with improved quantitation.

Courtesy Tata Memorial Center

MotionFree

Conventional Static

MotionFree

SUVmax 7.03, Volume 6.93cm^3

Conventional Static

SUVmax 2.42, Volume 16.8cm^3

Not all tracers are approved in all regions

HIGH QUALITY BRAIN IMAGING

System Configuration

DIQ 5R

Acquisition

260 MBq / 7.0 mCi 18F-FDG
115 minute uptake
7 minute acquisition

Clinical History

Patient referred to PET/CT for evaluation Astrocytoma

Patient Demographics

BMI 24.7

Takeaway

High Sensitivity combined with enhanced Q.Clear on Gen2 provides high quality images.

Courtesy Tata Memorial Center

Not all tracers are approved in all regions

IMPROVED LESION DETECTABILITY

System Configuration
DIQ 5R

Acquisition
18F-PSMA-1007
Dose: 4.3MBq/Kg
120 min uptake, 2 min/bed

Clinical History
Late 60ies; GS 4+5; 2015 robotic prostatectomy followed by hormonal Tx
PSA↑ Jul18-2.8
Negative A/P CT & NMBS for PD

Patient Demographics
BMI 28.1

Takeaway
Q.Clear enables improved lesion detectability which is seen in Left acetabulum lesion

Courtesy of Dr. Skoura, Bioatriki, Athens, Greece
*PET Radiopharmaceutical may not be approved by ministers of health in all regions

Q.Clear

VPHD

Not all tracers are approved in all regions

IMPROVED LESION DETECTABILITY

System Configuration

DIQ 5R

Acquisition

18F-PSMA-1007Dose: 316 MBq (Sep 2018)

120 min uptake Dose: 319 MBq (Jan 2019)

2 min/bed Recon: Q.Clear & VPHD

Clinical History

Early 60ies; 2011 Radical prostatectomy.GS 4+3; 201: localized RTx
Slow PSA↑ Sep18 - 0.25 ng/ml
Sep 2018: Single external iliac LN 4x3mm. No therapy or intervention started after this scan. Jan2019: 4months after previous 18F-PSMA scan, this single external iliac LN increased to size 5x3 and PSMA is well visible on Q.Cear, but also now visible on the iterative reconstruction

Patient Demographics

BMI 24.7

Takeaway

High Sensitivity combined with Q.Clear enabled treatment management

Courtesy of Dr. Skoura, Bioatriki, Athens, Greece
*PET Radiopharmaceutical may not be approved by ministers of health in all regions

4x3mm

Sep 2018

5x3mm

Q.Clear

Jan 2019

VPHD

Not all tracers are approved in all regions

CLINIAL EXCELLENCE AND EXPANSION

System Configuration

DIQ 5R

Acquisition

18F-PSMA-1007

120 min uptake

2 min/bed

Clinical History

18F-PSMA uptake in prostate gland infiltrating the left seminal vesicle, left external iliac lymph node 13x10mm, two very small left pararectal lymph nodes

Patient Demographics

BMI 24.2

Takeaway

High Sensitivity combined with Q.Clear enabled small lesion detectability.

Courtesy of Dr. Skoura, Bioatriki, Athens, Greece

PET Radiopharmaceutical may not be approved by ministers of health in all regions

9x7 & 7x6mm

Not all tracers are approved in all regions

LOW DOSE, HIGH QUALITY IMAGE

System Configuration

DIQ 5R

Acquisition

6 min acquisition
140MBq /3.79mCi FDG
60 minute uptake

Clinical History

Sarcoidosis.
Idiopathic dilated cardiomyopathy.

Patient Demographics

BMI 15.8

Takeaway

Nodules in both lung.
Suspicious of inflammation.
High Sensitivity enables low dose imaging.

Courtesy of Kyoto University, Japan.

HIGH SENSITIVITY, FAST SCAN

System Configuration

DIQ 4R

Acquisition

6 min acquisition

10.2mCi FDG

88 minute uptake

**Clinical History**

Malignant Melanoma
Solitary lesion.

Patient Demographics

BMI 31.7

Takeaway

High Sensitivity and Q.Clear enables faster acquisition and lesion detectability.

Courtesy of Istanbul University, Turkey

SUV Max 4.49

Not all tracers are approved in all regions

IMPROVED Q.CLEAR BRAIN ON GEN2

System Configuration

DIQ 5R

Acquisition

288.6MBq/ 7.8mCi of 18F-FDG

2beds, 3 min/bed

Q.Clear- B200

Patient Demographics

BMI: 23.8

Takeaway

New Q.Clear algorithm improves image quality in coronal and sagittal orientations.

Gen1

Gen2

Not all tracers are approved in all regions